沙库巴曲缬沙坦钠治疗慢性充血性心力衰竭的效果

Effect of Sacubitril Valsartan Sodium in the Treatment of Chronic Congestive Heart Failure

目的:探讨沙库巴曲缬沙坦钠治疗慢性充血性心力衰竭的效果。方法:选取2022年2月—2023年2月安顺市镇宁布依族苗族自治县人民医院收治的慢性充血性心力衰竭患者100例为研究对象,随机分为对照组和试验组,各50例。对照组应用缬沙坦胶囊治疗,试验组应用沙库巴曲缬沙坦钠治疗。比较两组心功能[左心室射血分数(LVEF)、每搏输出量(SV)、心排血量(CO)]、生化指标[醛固酮(ALD)、血管生成素Ⅱ(AngⅡ)、去甲肾上腺素(NE)]、治疗效果。结果:治疗前,两组LVEF、SV、CO水平比较,差异无统计学意义(P>0.05);治疗后,两组LVEF、SV、CO水平升高,试验组高于对照组,差异有统计学意义(P<0.05)。治疗前,两组ALD、AngⅡ、NE水平比较,差异无统计学意义(P>0.05);治疗后,两组ALD、AngⅡ、NE水平降低,试验组低于对照组,差异有统计学意义(P<0.05)。试验组治疗总有效率高于对照组,差异有统计学意义(P<0.001)。结论:沙库巴曲缬沙坦钠治疗慢性充血性心力衰竭可以改善患者的心功能、生化相关指标,提高治疗效果。

Objective:To explore the effect of sacubitril valsartan sodium in the treatment of chronic congestive heart failure.Methods:A total of 100 patients with chronic congestive heart failure admitted to the Anshun Zhenning Buyi and Miao Autono⁃mous County People's Hospital from February 2022 to February 2023 were selected as the research subjects and randomly divided into a control group and an experimental group,50 cases in each.The control group was treated with valsartan capsules,and the experimental group was treated with sacubitril valsartan sodium.The cardiac function[left ventricular ejection fraction(LVEF),stroke volume(SV),cardiac output(CO)],biochemical indicators[aldosterone(ALD),angiopoietinⅡ(AngⅡ),norepinephrine(NE)],treatment effect were compared between the two groups.Results:Before treatment,there was no statistically significant dif⁃ference in the LVEF,SV,and CO levels between the two groups(P>0.05);after treatment,the levels of LVEF,SV,and CO in the two groups increased,and the experimental group was higher than the control group,and the difference was statistically significant(P<0.05).Before treatment,there was no statistically significant difference in the levels of ALD,AngⅡ,and NE between the two groups(P>0.05);after treatment,the levels of ALD,AngⅡ,and NE in the two groups were reduced,and the experimental group was lower than the control group,and the difference was statistically significant(P<0.05).The total effective rate of treatment in the experimental group was higher than that in the control group,and the difference was statistically significant(P<0.001).Conclu⁃sion:Sacubitril valsartan sodium in the treatment of chronic congestive heart failure can improve patients'cardiac function and biochemical related indicators,and improve the therapeutic effect.